Monopar Therapeutics Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual report; the supplied filing text does not provide standalone fourth-quarter results. Monopar is a clinical-stage oncology biopharmaceutical company with no approved products or product-sales revenue.
Business context
The pipeline includes MNPR-101-Zr, an investigational uPAR-targeted imaging agent; MNPR-101-RIT, a radiotherapeutic in late preclinical development; camsirubicin, in a Phase 1b dose-escalation trial; and MNPR-202, in preclinical development. The company discontinued Validive after its Phase 2b/3 trial failed to meet the prespecified efficacy threshold.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $5.60 million | $7.59 million |
| General and administrative expense | $3.23 million | $2.95 million |
| Total operating expenses / operating loss | $8.83 million | $10.54 million |
| Interest income | $0.43 million | $0.02 million |
| Net loss | $8.40 million | $10.52 million |
| Net loss per share, basic and diluted | $0.61 | $0.83 |
| Net cash used in operating activities | $7.86 million | $7.23 million |
| Cash and cash equivalents at year-end | $7.27 million | $8.19 million |
Margins: Not meaningful because the company reported no revenue. Debt and liquidity: The filing reports no borrowings; year-end liabilities were $1.76 million, primarily accounts payable, accrued expenses and other current liabilities. Cash and current assets were $7.33 million at year-end; the company held no investments classified separately from cash equivalents at that date.
Management estimated that funds available as of March 8, 2024, including subsequent ATM proceeds, would support planned operations at least through June 30, 2025. It also said additional funding would be needed for further development, with tens of millions of dollars cited to complete the MNPR-101 radiopharmaceutical and camsirubicin clinical programs. This runway estimate depends on assumptions and is not assured.
Material changes versus 2022
- Net loss narrowed by approximately $2.11 million, primarily as operating expenses fell and interest income increased.
- R&D expense declined by approximately $1.99 million, mainly because Validive was discontinued and camsirubicin trial and manufacturing costs decreased; increased MNPR-101 activity partly offset the reduction.
- G&A expense increased by $0.29 million, primarily due to personnel costs and stock-based compensation.
- Operating cash use increased by approximately $0.63 million. The smaller overall decline in cash partly reflected Treasury bill maturities and increased ATM financing.
- The company sold 1,793,441 shares through its ATM in 2023, generating approximately $2.07 million net proceeds. From January 1 to March 8, 2024, it sold a further 2,545,305 shares for approximately $3.19 million net proceeds; shares outstanding were 17,454,925 on March 8, 2024.
Outlook, commentary and key risks
- In February 2024, Monopar received Australian ethics clearance for a planned Phase 1 MNPR-101-Zr dosimetry study in approximately 12 patients. The study is intended to assess tumor uptake, biodistribution and safety; human efficacy has not been established.
- Camsirubicin was enrolling at the fifth Phase 1b dose cohort, 650 mg/m². Management’s development plans depend on trial data; prior reported clinical benefit came from an earlier study and does not establish efficacy in the ongoing trial.
- Management reported promising preclinical MNPR-101 imaging and therapeutic results. These are animal-model findings, not clinical proof of benefit.
- The company expects continued losses and plans to seek additional capital through equity, debt, collaborations or grants. Equity financing may dilute shareholders; partnerships may require sharing rights or economics. Failure to obtain funding could require delays, prioritization or termination of programs.
- Nasdaq granted an additional 180 days on February 27, 2024, to regain the $1.00 minimum bid-price requirement by August 26, 2024. Failure could lead to delisting; a reverse split or appeal may be considered, with uncertain effects.
- Key operating risks include limited and potentially costly radioisotope supply, short radiopharmaceutical shelf life and delivery logistics, reliance on third-party manufacturers and trial providers, clinical and regulatory uncertainty, competition, and inflation and geopolitical disruption to supply and financing.
- The XOMA license may require clinical, regulatory and sales milestone payments totaling up to $14.925 million if achieved; no milestones had been reached as of March 8, 2024, and the agreement carries no sales royalties. No material legal proceedings were reported.
Most important facts for investors to verify
- Actual cash burn, cash runway and financing needs in subsequent filings, including the assumptions behind the June 30, 2025 runway estimate.
- MNPR-101-Zr trial initiation, enrollment, safety and imaging results, and any follow-on therapeutic trial plans.
- Camsirubicin Phase 1b safety, dose-escalation progress and evidence supporting any next-stage development decision.
- Nasdaq bid-price compliance, any reverse split or appeal, and subsequent share issuance and dilution.
- Availability, cost and delivery reliability of radioisotopes and other clinical materials, alongside the status of manufacturing arrangements.
Reporting notes: The independent auditor gave an unqualified opinion on the financial statements. Management reported effective internal control over financial reporting; the auditor was not engaged to audit or express an opinion on internal controls.